Pfizer drug works on rare pancreatic cancer-study

NEW YORK (Reuters) - A study of Pfizer Inc's Sutent was halted early after the medicine delayed progression of a rare form of pancreatic cancer affecting tens of thousands of people globally, including Apple Inc. CEO Steve Jobs.

An independent safety board monitoring the late-stage study recommended halting it after concluding that patients on Sutent stayed free of disease progression for longer than those on placebo plus best supportive care, Pfizer said on Thursday.

Given the clearly favorable trend, patients who took Sutent in the trial will be allowed to continue doing so, and those who were given placebos will now have the option of taking the drug instead.

Patients in the study had advanced pancreatic islet cell tumors, also known as neuroendocrine cancer. It occurs in specialized cells of the pancreas that secrete a variety of hormones, including insulin and enzymes involved in digestion.

Other types of pancreatic cancer occur in ducts of the pancreas - small tubes that transport digestive enzymes produced in the pancreas to the small intestine.

"This form of pancreatic cancer involves only about 5 percent of all pancreatic cancer cases, and grows and spreads more slowly" than other types of pancreatic cancer, said Mace Rothenberg, a senior Pfizer research executive.

But when surgery to remove the cancer is not possible, or when cancer returns after surgery, Rothenberg said life expectancy is only several years, and patients can experience difficult symptoms, such as life-threatening high levels of insulin and stomach ulcers.

Jobs, who co-founded Apple Computer and turned it into a consumer juggernaut after returning as CEO a decade ago, underwent surgery in 2004 to remove an islet cell tumor from his pancreas.

In January, Jobs said he would take a five-month medical leave because his health problems were more complex than originally thought.

The tech innovator acknowledged he had been losing weight throughout 2008 and said his doctors determined a hormone imbalance had been depriving him of vital proteins. That triggered speculation his cancer had returned and was upsetting hormones involved in digestion.

Sutent, which had fourth-quarter sales of $220 million, is currently approved for treating advanced kidney cancer as well as gastrointestinal tract tumors.

Pfizer is also testing the medicine in late-stage studies against cancers of the breast, lungs, colon, prostate and liver.

Shares of Pfizer were up 6.6 percent to $13.63 in midday trading, amid a 3.75 percent rise in the American Stock Exchange Pharmaceutical Index <.DRG> of large U.S. and European drugmakers.

Copyright © 2009 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.